|
|
|||
|
||||
OverviewKinase Targets and Drug Discovery covers the critical role of kinases as regulators of cellular functions and their implications in a range of diseases, from cancers to cardiovascular disorders and inflammatory conditions. Readers will explore foundational concepts on the functions of kinases, the role of kinase inhibitors in disease therapy, and challenges faced. The second section focuses on innovative strategies in kinase drug discovery, covering screening and computational approaches, along with the development of covalent, macrocyclic, allosteric inhibitors, and kinase degraders. Final sections examine clinical applications, detailing how kinase inhibition can be harnessed for cancer therapies, non-oncologic diseases, and even non-catalytic functions. This book will serve as an indispensable resource for pharmacologists, medicinal chemists, and researchers in both academia and industry. By bridging the gap between foundational research and clinical application, it equips professionals with the latest insights and practical approaches to advance their understanding to contribute meaningfully to the evolving landscape of drug discovery. Full Product DetailsAuthor: Xiaoyun Lu, PhD (Jinan University, China)Publisher: Elsevier Science Publishing Co Inc Imprint: Academic Press Inc Weight: 0.450kg ISBN: 9780443439742ISBN 10: 0443439745 Pages: 374 Publication Date: 27 April 2026 Audience: Professional and scholarly , Professional & Vocational Format: Paperback Publisher's Status: Forthcoming Availability: Not yet available This item is yet to be released. You can pre-order this item and we will dispatch it to you upon its release. Table of ContentsPart I: Kinase as drug target: An overview 1. Introduction to Kinases and Their Functions 2. Kinase Inhibitors in Diseases Therapy 3. Challenges in Kinase Inhibitors Discovery Part II: Strategies in Kinase Drug Discovery 4. Screening Approaches for Kinases 5. Computational Approaches for Kinases 6. Covalent Inhibitors of Kinase 7. Macrocyclic Inhibitors of Kinase 8. Allosteric Inhibitors of Kinase 9. Kinase Degraders 10. Kinase Activators Part III: Clinical Indications for Kinase Inhibitors 11. Kinase Inhibition for Cancer (Contain Immuno-Oncology) 12. Kinase Inhibition for Nononcologic Diseases 13. Kinase Inhibition for Non-Catalytic FunctionReviewsAuthor InformationXiaoyun Lu studied Medicinal Chemistry at China Pharmaceutical University and received her Ph.D. in 2010. After working for six years in Guangzhou Institutes of Biomedicine and Health (GIBH), she moved to the School of Pharmacy at Jinan University in 2016. Her research interests include the design of new generation of kinase inhibitors to overcome clinical resistance of cancers. She has been involved in the design and development of EGFR, DDRs, FGFR4, and TRKs inhibitors. Among them, two drug-like inhibitors of kinase have been into clinic. She has published about 100 SCI papers and co-invented 40 patents, received the Special Professor of Changjiang Scholars of Ministry of Education (2024), the National Outstanding Youth Fund (2019), China Pharmaceutical Association - Servier Pharmaceutical Chemistry Award (2014) and Chinese Academy of Sciences Lu Jiaxi Young Talent Award (2015). She currently serves as editorial Board Member of Journal of Medicinal Chemistry, Acta Pharmaceutica Sinica B, Chinese Chemical Letters, etc. Tab Content 6Author Website:Countries AvailableAll regions |
||||